# Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy

> **NCT06236061** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 718 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** LCZ
- **DRUG:** LCZ/AML 200 mg/2.5 mg
- **DRUG:** LCZ/AML 200 mg/5 mg
- **DRUG:** LCZ/AML 200 mg/10 mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06236061
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-08
- **Primary completion:** 2025-05-28
- **Final completion:** 2025-12-23
- **Target enrollment:** 718 (ACTUAL)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06236061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06236061, "Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT06236061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*